GSK Keeps Slimming Down With $270M Sale Of Aussie Drugs
GlaxoSmithKline PLC announced Wednesday that it would sell 25 of its less-profitable Australian prescription drugs to South Africa's Aspen Pharmacare Holdings Ltd. for £172 million ($270 million), continuing to shed noncore...To view the full article, register now.
Already a subscriber? Click here to view full article